Sweden declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 23 of 49 of this archive, newest first.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
The evidence base is thin and the document says so, which is to its credit.
Efficacy was never the question in this appraisal. Duration of treatment was.
The observation that closes a facility is rarely the dramatic one.
The observation that closes a facility is rarely the dramatic one.
The observation that closes a facility is rarely the dramatic one.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
The document is four pages. Three of them are about dates.
The evidence base is thin and the document says so, which is to its credit.
The observation that closes a facility is rarely the dramatic one.
The document is four pages. Three of them are about dates.
A proper account of an operation that existed, and of what closing it cost.
The document is four pages. Three of them are about dates.
The observation that closes a facility is rarely the dramatic one.
The observation that closes a facility is rarely the dramatic one.